Board of Directors
Arie Belldegrun, MD, FACS
Vice Chairman, Board of Directors
Chairman, Scientific Advisory Board
Cougar Biotechnology, Inc.
Chief, Division of Urologic Oncology
David Geffen School of Medicine at UCLA
Dr. Belldegrun joined Cougar Biotechnology, Inc. in December 2003
as Vice Chairman of the Board of Directors and Chairman of the Scientific
Advisory Board. Dr. Belldegrun is Chief of the Division of Urologic
Oncology and holds the Roy and Carol Doumani Chair in Urologic Oncology
at the David Geffen School of Medicine at the University of California,
Los Angeles (UCLA).
He is also the Founder of Agensys, Inc., a privately held biotechnology
company focused on the development of fully human monoclonal antibodies
to treat solid tumor cancers based on Agensys’ proprietary
targets. Dr. Belldegrun served as founding Chairman of Agensys from
1997-2002 and currently serves on Agensys’ Board of Directors
and as a consultant.
He completed his medical degree at the Hebrew University Hadassah
Medical School in Jerusalem, his post graduate fellowship at the
Weizmann Institute of Science and his residency in Urology at Harvard
Medical School. Prior to UCLA, Dr. Belldegrun was at the National
Cancer Institute/NIH as a research fellow in surgical oncology under
Steven A. Rosenberg, MD, PhD. He is certified by the American Board
of Urology and a Fellow of the American College of Surgeons.
Dr Belldegrun is also on the scientific boards of several biotechnology
and pharmaceutical companies and serves as a reviewer for many medical
journals and granting organizations including the Journal of Urology
and the American Foundation of Urologic Diseases. In addition to
holding several patents, Dr. Belldegrun is the author of several
books on prostate and kidney cancers and has written over 250 scientific
publications with an emphasis on urologic oncology, particularly
kidney, prostate and bladder cancers.
Lindsay A. Rosenwald, MD
Paramount Capital, Inc.
Dr. Rosenwald is the Chairman and Chief Executive of the Paramount
Capital group of companies. The Paramount Capital group of companies
specializes in asset management, investment banking, venture capital
and direct investing within the biotechnology and life-sciences
industry. Paramount Capital Asset Management, Inc. manages investor
assets through domestic and offshore hedge funds, as well as private
equity. Paramount Capital Inc., a NASD member broker dealer, specializes
in conducting private placement offerings for public and private
development stage biotechnology companies. Paramount Capital Investments,
LLC is a venture capital organization that takes a controlling interest
in public and private companies, including start-ups and distressed
Dr. Rosenwald has been a Wall Street biotechnology entrepreneur
for over 17 years and has been instrumental in the founding and
re-capitalization of dozens of public and private biotechnology
and life-sciences companies. Paramount’s portfolio companies
have already seen three new chemical entities approved by the FDA
and currently have dozens of compounds in clinical trials. One portfolio
company, PolaRx BioPharmaceuticals, Inc., received final marketing
approval for its cancer drug, Arsenic Trioxide, only 30 months after
the first patient was treated in a corporate clinical trial, a record
in the industry. In addition to Cougar Biotechnology, Dr. Rosenwald
has financed or founded Cypress Bioscience, Inc., Bradley Pharmaceuticals,
Inc., Genta, Inc, Repligen Corporation, Discovery Laboratories,
Inc., Avigen, Inc., Indevus Pharmaceuticals, Inc., Cardiome Pharma
Corp., Keryx Biopharmaceuticals, Inc., Neose Technologies Inc.,
Cell Therapeutics, Inc., Biocryst Pharmaceuticals, Inc and Hudson
Health Sciences, Inc.
Dr. Rosenwald received his M.D. from Temple University School of
Medicine and his B.S. in Finance from Pennsylvania State University.
Alan H. Auerbach
Chief Executive Officer/President
Cougar Biotechnology, Inc.
Mr. Auerbach joined Cougar
Biotechnology, Inc. in May 2003 as Chief Executive
Officer and President. From
June 1998 to April 2003, Mr. Auerbach was Vice President, Senior
Research Analyst at Wells Fargo Securities where he was responsible
for research coverage of small and middle capitalization biotechnology
companies, with a focus on companies in the field of oncology. He
had primary responsibility for technical, scientific and clinical
due diligence as well as selection of biotechnology companies followed
by Wells Fargo Securities. During 2002, Mr. Auerbach ranked second
in the NASDAQ/Starmine survey of analyst performance for stock picking
in biotechnology. From August 1997 to May 1998, Mr. Auerbach was
Vice President, Research Analyst at the Seidler Companies, Inc.,
where he was responsible for research coverage of small capitalization
biotechnology companies. Prior to his work as a biotechnology analyst,
Mr. Auerbach worked for Diagnostic Products Corporation, where he
designed and implemented clinical trials in the field of oncology.
Mr. Auerbach received his B.S. in biomedical engineering from Boston
University and his M.S. in biomedical engineering from the University
of Southern California.
David M. Tanen
David M. Tanen is currently a partner in Two River
Group Holdings, LLC, a New York based venture capital
group focused on creating new companies to in-license
and develop novel technologies. From 1996 until
September 2004, Mr. Tanen has served as an associate
director of Paramount Capital, Inc., where he has
helped found other biotechnology companies. Mr. Tanen
also serves as a member of the Board of Directors of
Chiral Quest Inc. (OTCBB: CQST) and Manhattan
Pharmaceuticals, Inc. (OTCBB: MHTT) both publicly
traded companies, and as an officer and/or director of
several other privately held development-stage
biotechnology companies. Mr. Tanen received the B.A.
degree from George Washington University, and the J.D.
degree from Fordham University School of Law.
Harold J. Meyers
Mr. Meyers' career encompasses over 45 years of professional experience in various aspects of the financial services industry, including being the founder of Los Angeles based H.J. Meyers and Company from 1982-1994, serving as Managing Director of Wells Fargo Investments (formerly Van Kasper & Company) from 1995-2003 and serving in his current position as Senior Vice President of A.G. Edwards & Sons, Inc., since 2003. Mr. Meyers holds a B.S. from the University of Denver.